Introduction and Objectives: We initiated this multicenter study to integrate important risk factors to create a nomogram for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) for clinician decision-making. Patients and Methods: Between April 2011 and March 2022, 2281 HCC patients with an HBV-related diagnosis were included. All patients were randomly divided into two groups in a ratio of 7:3 (training cohort, n = 1597; validation cohort, n = 684). The nomogram was built in the training cohort via Cox regression model and validated in the validation cohort.

This article supports SDG 3 by developing noninvasive tools for predicting liver fibrosis in autoimmune hepatitis patients.

This study supports SDG 3 by examining the impact of early liver transplantation on hospital admissions for alcoholic hepatitis.

This study supports SDG 3 by developing predictive tools for treatment outcomes in chronic hepatitis B patients.

This article supports SDG 3 by providing global prevalence data on occult HBV infection in younger populations.

This study contributes to SDG 3 by addressing safety improvements in hepatitis B treatment regimens.

This article supports SDG 3 by improving diagnostic capabilities for hepatitis E virus in blood donors.

This article supports SDG 3 by evaluating the outcomes of early liver transplantation for alcohol-associated hepatitis.

This study supports SDG 3 by providing insights into the mechanisms of autoimmune hepatitis and potential therapeutic targets.

This study supports SDG 3 by investigating the relationship between NAFLD and liver fibrosis in chronic hepatitis B patients.